Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Трансмуральное заживление и модифицирующий заболевание эффект гуселькумаба у пациентов с болезнью Крона (REASON)

2 ноября 2026 г. обновлено: Janssen-Cilag Ltd.

Фаза 3b, одногрупповое, открытое, многоцентровое исследование для оценки трансмурального заживления и модифицирующего заболевание эффекта гуселькумаба у пациентов с болезнью Крона

The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.

Обзор исследования

Статус

Активный, не рекрутирующий

Условия

Вмешательство/лечение

Тип исследования

Интервенционный

Регистрация (Действительный)

120

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

  • Австралия
      • Adelaide, Австралия, 5011
        • The Queen Elizabeth Hospital
      • Concord, Австралия, 2139
        • Concord Repatriation General Hospital
      • Melbourne, Австралия, 3076
        • Northern Hospital
      • Murdoch, Австралия, 6150
        • Fiona Stanley Hospital
      • South Brisbane, Австралия, 4101
        • Mater Hospital Brisbane
  • Бельгия
      • Ghent, Бельгия, 9000
        • AZ Maria Middelares
      • Liège, Бельгия, 4000
        • CHU de Liege
      • Sint-Niklaas, Бельгия
        • Vitaz
  • Бразилия
      • Macaé, Бразилия, 27910-020
        • Cliged
      • Passo Fundo, Бразилия, 99010-120
        • Instituto Mederi de Pesquisa e Saude
      • Porto Alegre, Бразилия, 90430001
        • NPCRS Nucleo de Pesquisa Clinica do Rio Grande do Sul
      • Votuporanga, Бразилия, 15501-405
        • INTEGRAL Pesquisa e Ensino
  • Германия
      • Augsburg, Германия, D-86158
        • Klinikum Augsburg
      • Berlin, Германия, 10117
        • Charite Universitaetsmedizin Berlin
      • Berlin, Германия, 10825
        • Praxis Fur Gastroenteroligie
      • Dachau, Германия, 85221
        • Medizinisches Versorgungszentrum (MVZ) Dachau
      • Frankfurt, Германия, 60590
        • Universitatsklinikum Frankfurt/ Medizinische Klinik 1
      • Göttingen, Германия, 37075
        • Universitatsmedizin Gottingen
      • Halle, Германия, 06108
        • Studiengesellschaft Mitteldeutschland GmbH
      • Hanover, Германия, 30625
        • Medizinische Hochschule Hannover
      • Kiel, Германия, 24105
        • Universitatsklinikum Schleswig Holstein
      • Lüneburg, Германия, 21339
        • Staedtisches Klinikum Lueneburg
      • Münster, Германия, 48155
        • MVZ Portal 10
      • Pforzheim, Германия, 75179
        • Siloah St Trudpert Klinikum
      • Ulm, Германия, 89081
        • Universitaetsklinikum Ulm
  • Израиль
      • Haifa, Израиль, 31096
        • Rambam Medical Center
      • Holon, Израиль, 58100
        • The Edith Wolfson Medical Center
      • Jerusalem, Израиль, 91200
        • Hadassah Medical Organization
      • Nahariya, Израиль, 2210001
        • Galilee Medical Center
      • Petah Tikva, Израиль, 49100
        • Rabin Medical Center
      • Ramat Gan, Израиль, 5265601
        • The Chaim Sheba Medical Center
      • Tel Aviv, Израиль, 6423906
        • Tel Aviv Sourasky Medical Center
  • Испания
      • Alicante, Испания, 3010
        • Hosp. Gral. Univ. Dr. Balmis
      • Córdoba, Испания, 14004
        • Hosp Reina Sofia
      • Ferrol, Испания, 15405
        • Complejo Hosp Univ. de Ferrol
      • Ferrol, Испания, 15405
        • Hosp. Univ. de La Paz
      • Madrid, Испания, 28006
        • Hosp. Univ. de La Princesa
      • Madrid, Испания, 28222
        • Hosp. Univ. Pta. de Hierro Majadahonda
      • Valencia, Испания, 46010
        • Hosp. Clinico Univ. de Valencia
      • Vigo, Испания, 36213
        • Hosp. Alvaro Cunqueiro
  • Италия
      • Bologna, Италия, 40138
        • Azienda Ospedaliera Policlinico S. Orsola-Malpighi
      • Milan, Италия, 20132
        • IRCCS Ospedale San Raffaele
      • Milan, Италия, 20121
        • ASST Fatebenefratelli Sacco
      • Naples, Италия, 80131
        • Universita Di Napoli Federico Ii
      • Pontedera Pisa, Италия, 56025
        • ASL Toscana Nord Ovest PO Valdera Ospedale Lotti
      • Rho, Италия, 20017
        • Asst Rhodense - Ospedale Di Rho
      • Roma, Италия, 00133
        • Fondazione Policlinico Tor Vergata
      • Roma, Италия, 00168
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Roma, Италия, 00128
        • Universita Campus Bio-Medico di Roma
      • Rozzano, Италия, 20089
        • IRCCS Humanitas Rozzano-IBD Center Malattie Infiammatorie Croniche Intestinali
      • San Giovanni Rotondo, Италия, 71013
        • IRCCS Ospedale Casa Sollievo della Sofferenza
  • Канада
    • Alberta
      • Calgary, Alberta, Канада, T2N 4Z6
        • Foothills Hospital
    • Ontario
      • London, Ontario, Канада, N6A 5A5
        • Western University & London Health Sciences Centre
    • Quebec
      • Montreal, Quebec, Канада, H4J 1C5
        • Hopital du Sacre-Coeur de Montreal
  • Польша
      • Bydgoszcz, Польша, 85 231
        • NZOZ Centrum Medyczne KERmed
      • Rzeszów, Польша, 35-326
        • Centrum Medyczne Medyk
      • Torun, Польша, 87 100
        • GASTROMED Sp. z o.o.
      • Warsaw, Польша, 00-728
        • WIP Warsaw IBD Point Profesor Kierkus
      • Wroclaw, Польша, 52-416
        • Centrum Medyczne Oporow
      • Wroclaw, Польша, 54 144
        • EuroMediCare Szpital Specjalistyczny z Przychodnia
      • Wroclaw, Польша, 50 449
        • Melita Medical Sp. z o.o.
      • Zamość, Польша, 22-400
        • ETG Zamosc
  • Словакия
      • Banská Bystrica, Словакия, 975 17
        • FNsP F.D.R. Banska Bystrica
      • Bratislava, Словакия, 811 09
        • Cliniq s.r.o.
      • Košice, Словакия, 040 13
        • ENDOMED s.r.o
      • Nitra, Словакия, 949 01
        • KM Management spol. s r.o.
      • Prešov, Словакия, 080 01
        • GASTRO I. s.r.o.
  • Соединенные Штаты
    • California
      • San Francisco, California, Соединенные Штаты, 94115
        • Center for Colitis and Crohns Disease University of California
    • Illinois
      • Chicago, Illinois, Соединенные Штаты, 60637
        • The University of Chicago Medical Center (UCMC)
    • Missouri
      • St Louis, Missouri, Соединенные Штаты, 63110
        • Washington University School Of Medicine
    • South Carolina
      • Charleston, South Carolina, Соединенные Штаты, 29425
        • Medical University of South Carolina
  • Тайвань
      • Changhua, Тайвань, 500
        • Chang-Hua Christian Hospital
      • New Taipei City, Тайвань, 22060
        • Far Eastern Memorial Hospital
      • Taipei, Тайвань, 10002
        • National Taiwan University Hospital
      • Taipei, Тайвань, 11217
        • Taipei Veterans General Hospital
  • Франция
      • Amiens, Франция, 80054
        • CHU Amiens Picardie
      • Clermont-Ferrand, Франция, 63000
        • CHU de Clermont Ferrand
      • Lille, Франция, 59000
        • CHRU de Lille Hopital Claude Huriez
      • Marseille, Франция, 13915
        • Aphm - Hopital Nord
      • Nantes, Франция, 44000
        • CHU de Nantes hotel Dieu
      • Paris, Франция, 75018
        • APHP - Hopital Bichat - Claude Bernard
  • Чехия
      • Hradec Králové, Чехия, 500 12
        • Hepato-gastroenterologie HK, s.r.o.
      • Prague, Чехия, 19000
        • ISCARE a.s.
      • České Budějovice, Чехия, 370 87
        • Nemocnice Ceske Budejovice a s

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

18 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Has luminal Crohn's disease (CD) of at least 3 months duration (defined as a minimum of 12 weeks), with colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy
  • Has clinically active CD, defined as a baseline CD activity index (CDAI) score greater than or equal to (>=)220 but <=450 and either: a. Mean daily stool frequency (SF) count >=4, based on the unweighted CDAI component of the number of liquid or very soft stools or b. Mean daily AP score >=2, based on the unweighted CDAI component of abdominal pain (AP)
  • Active transmural activity in at least one segment (segmental magnetic resonance index of activity [MaRIA] >= 11)
  • a. Has demonstrated inadequate response/intolerance to conventional therapy; b. Has previously demonstrated lack of initial response (that is, primary non-responders), responded initially but then lost response with continued therapy (that is, secondary non-responders), or was intolerant to a maximum of 1 class of advanced therapies at a dose approved for the treatment of Crohn's disease (that is, janus kinase [JAK] inhibitors, infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab, or approved biosimilars for these agents)

Exclusion Criteria:

  • Has complications of Crohn's disease, such as symptomatic strictures or stenoses (unless less than [<]3 centimeter (cm) dilatation and not symptomatic or displaying associated fistula/fistulae and/or or abscess), fibrotic stenosis, internal fistulas, short gut syndrome, or any other manifestation, that might be anticipated to require surgery, could preclude the use of the CDAI to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with guselkumab
  • Currently has or is suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained and adequately treated at least 3 weeks before baseline, or 8 weeks before baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery. Participants with active perianal fistulas may be included if there are no associated stenoses, no anticipated surgery and no abscesses currently identified
  • Has had any kind of bowel resection within 6 months, or any other intra-abdominal or other major surgery within 12 weeks before baseline
  • Has a draining (that is, functioning) stoma or ostomy
  • Has a stool culture or other examination positive for an enteric pathogen, including Clostridioides difficile (formerly known as Clostridium difficile) toxin, in the previous 4 months, unless a repeat examination is negative and there are no signs of ongoing infection with that pathogen

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Н/Д
  • Интервенционная модель: Одногрупповое задание
  • Маскировка: Нет (открытая этикетка)

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Guselkumab

Participants will receive guselkumab 200 milligram (mg) intravenously (IV) at week 0, 4 and 8. Afterwards, participants will be alternately assigned at study level to 2 dose cohorts, high dose (200 mg subcutaneous (SC) every 4 weeks (Q4W) starting at week 12) through week 92 or low dose (100 mg SC every 8 weeks (Q8W) starting at week 16) through week 88. Starting at Week 24, participants in the low-dose cohort will be permitted to escalate to the 200 mg SC Q4W regimen if they are symptomatic and at the discretion of the investigator.
Лекарство: Guselkumab

Guselkumab will be administered IV and SC.

Другие имена:
  • CNTO1959; ТРЕМФЯ

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Percentage of Participants Achieving a Magnetic Resonance Index of Activity (MaRIA) Less Than (<)11 in All Intestinal Segments at Week 48
Временное ограничение: At Week 48

Percentage of participants achieving a MaRIA <11 in all intestinal segments at Week 48 will be reported. The MaRIA scoring system is used to grade severity in Crohn's Disease (CD) by assessing ileocolonic CD activity on contrast-enhanced magnetic resonance imaging (MRI) enterography. Active disease is defined as a MaRIA score greater than or equal to (>=)7 whereas severe disease is defined as a MaRIA score >=11.
At Week 48

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Percentage of Participants Achieving a MaRIA <11 in All Intestinal Segments at Weeks 16 and 96.
Временное ограничение: At Weeks 16 and 96

Percentage of participants achieving a MaRIA <11 in all intestinal segments at Weeks 16 and 96 will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic CD activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score >=7 whereas severe disease is defined as a MaRIA score >=11.
At Weeks 16 and 96
Percentage of Participants Achieving a MaRIA <11 and a Reduction of >=5 Points From Baseline in All Segments at Weeks 16, 48, and 96
Временное ограничение: At Weeks 16, 48, and 96

Percentage of participants achieving a MaRIA <11 and a reduction of >=5 points from baseline in all segments at Weeks 16, 48, and 96 will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic Crohn disease activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score >=7 whereas severe disease is defined as a MaRIA score >=11.
At Weeks 16, 48, and 96
Percentage of Participants Achieving a MaRIA <11 in All Segments and Endoscopic Remission at Weeks 48 and 96
Временное ограничение: At Week 48 and 96

Percentage of participants achieving a MaRIA <11 in all segments and endoscopic remission at Weeks 48 and 96 will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic CD activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score >=7 whereas severe disease is defined as a MaRIA score >=11. Endoscopic remission is defined as simple endoscopic score for Crohn's Disease (SES-CD) total score <=4 with at least 2 points reduction from baseline and no sub-score >1 in any individual component.
At Week 48 and 96
Percentage of Participants Achieving a MaRIA <11 in All Segments and Endoscopic Response at Weeks 48 and 96.
Временное ограничение: At Weeks 48 and 96

Percentage of participants achieving a MaRIA <11 in all segments and endoscopic response at Weeks 48 and 96 will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic CD activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score >=7 whereas severe disease is defined as a MaRIA score >=11. Endoscopic Response is defined as >=50% improvement from baseline in simple endoscopic score for Crohn's Disease (SES-CD) total score or SES-CD total score <=2.
At Weeks 48 and 96
Percentage of Participants Achieving a MaRIA <11 in All Segments, Patient-Reported Outcome-2 (PRO-2) Remission, and No Worsening of Abdominal Pain (AP) or Stool Frequency (SF) From Baseline
Временное ограничение: At Weeks 16, 48 and 96

Percentage of participants achieving a MaRIA <11 in all segments and PRO-2 remission and no worsening of abdominal pain (AP) or stool frequency (SF) from baseline will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic CD activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score greater than or equal to (>=)7 whereas severe disease is defined as a MaRIA score >=11. PRO-2 remission is defined as defined as AP mean daily score <=1 and a SF mean daily score <=3, and no worsening of AP or SF from baseline.
At Weeks 16, 48 and 96
Percentage of Participants Achieving a MaRIA <11 in All Segments and Biomarkers Remission
Временное ограничение: At Weeks 16, 48 and 96

Percentage of participants achieving a MaRIA <11 in all segments and biomarkers remission will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic CD activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score >=7 whereas severe disease is defined as a MaRIA score >=11. Biomarker remission is defined as CRP <=3 mg/L and fecal calprotectin (fCal) <=250 mcg/g.
At Weeks 16, 48 and 96
Percentage of Participants Achieving a MaRIA <11 in All Segments, PRO-2, and Endoscopic Remission
Временное ограничение: At Weeks 48 and 96

Percentage of participants achieving a MaRIA <11 in all segments, PRO-2, and endoscopic remission will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic CD activity on contrast-enhanced MRI enterography. The MaRIA scale is based on features that are predictors for active disease; bowel wall thickness, presence of mucosal ulcers, presence of mural edema, measurement of WSI before and after IV contrast administration and RCE of the intestinal wall. Active disease is defined as a MaRIA score greater than or equal to (>=)7 whereas severe disease is defined as a MaRIA score >=11. PRO is defined as defined as AP mean daily score <=1 and a SF ) mean daily score <=3, and no worsening of AP or SF from baseline. Endoscopic remission is defined as SES-CD total score <=4 with at least 2 points reduction from baseline and no sub-score >1 in any individual component.
At Weeks 48 and 96
Percentage of Participants Achieving a MaRIA <7 in All Intestinal Segments at Weeks 16, 48 and 96
Временное ограничение: At Weeks 16, 48 and 96

Percentage of participants achieving a MaRIA <7 in all intestinal segments at Weeks 16, 48 and 96 will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic Crohn disease activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score >=7 whereas severe disease is defined as a MaRIA score >=11.
At Weeks 16, 48 and 96
Percentage of Participants Achieving a MaRIA <7 in All Segments and Endoscopic Remission at Weeks 48 and 96
Временное ограничение: At Weeks 48 and 96

Percentage of participants achieving a MaRIA <7 in all segments and endoscopic remission at Weeks 48 and 96 will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic CD activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score greater than or equal to (>=)7 whereas severe disease is defined as a MaRIA score >=11. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic Crohn disease activity on contrast-enhanced MRI enterography. The MaRIA scale is based on features that are predictors for active disease; bowel wall thickness, presence of mucosal ulcers, presence of mural edema, measurement of WSI before and after IV contrast administration and RCE of the intestinal wall. Active disease is defined as a MaRIA score greater than or equal to (>=)7 whereas severe disease is defined as a MaRIA score >=11.
At Weeks 48 and 96
Absolute Value of Global Simple MaRIA Score Through Week 96
Временное ограничение: Baseline up to Week 96

Absolute Value of global simple MaRIA score through Week 96 will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic Crohn disease activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score greater than or equal to (>=)7 whereas severe disease is defined as a MaRIA score >=11.
Baseline up to Week 96
Change From Baseline in the Global Simple MaRIA Score Through Week 96
Временное ограничение: Up to Week 96

Change from baseline in the global simple MaRIA score through Week 96 will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic CD activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score >=7 whereas severe disease is defined as a MaRIA score >=11.
Up to Week 96
Percentage of Participants Achieving a MaRIA <7 in All Intestinal Segments and Not Receiving Corticosteroids at Weeks 16, 48, and 96
Временное ограничение: At Weeks 16, 48, and 96

Percentage of participants achieving a MaRIA <7 in all intestinal segments and not receiving corticosteroids at Weeks 16, 48, and 96 will be reported. The MaRIA scoring system is used to grade severity in CD by assessing ileocolonic CD activity on contrast-enhanced MRI enterography. Active disease is defined as a MaRIA score >=7 whereas severe disease is defined as a MaRIA score >=11.
At Weeks 16, 48, and 96
Percentage of Participants Achieving Transmural Segmental Response with Intestinal Ultrasound (IUS) at Weeks 4, 8, 16, 48, and 96
Временное ограничение: Baseline, at Weeks 4, 8, 16, 48, and 96

Percentage of participants achieving transmural segmental response with IUS at Weeks 4, 8, 16, 48, and 96 will be reported. Transmural segmental response with IUS is defined as a reduction from baseline of 25 percent (%) in BWT or a reduction from baseline of bowel wall thickness (BWT) >=2 mm or a reduction from baseline of BWT >=1 millimeter (mm) plus a decrease from baseline in color doppler signal (CDS) >=1 point.
Baseline, at Weeks 4, 8, 16, 48, and 96
Percentage of Participants with Transmural Response (total) at Weeks 4, 8, 16, 48, and Week 96
Временное ограничение: Baseline, at Weeks 4, 8, 16, 48, and Week 96

Percentage of participants with transmural response (total) at Weeks 4, 8, 16, 48, and Week 96 will be reported. Transmural segmental response with IUS is defined as: a reduction from baseline of 25 percent (%) in BWT or a reduction from baseline of BWT >=2 millimeter (mm) or a reduction from baseline of BWT >=1 mm plus a decrease from baseline in color doppler >=1 point, per baseline pathological segment. Transmural response (total) requires that at least one pathological segment at baseline fulfills the criteria.
Baseline, at Weeks 4, 8, 16, 48, and Week 96
Percentage of Participants Achieving Transmural Remission with IUS at Weeks 4, 8, 16, 48, and 96
Временное ограничение: At Weeks 4, 8, 16, 48, and 96

Percentage of participants achieving transmural remission with IUS at Weeks 4, 8, 16, 48, and 96 will be reported. Transmural remission with IUS is defined as BWT <=3 mm for ileum and colon plus color doppler signal 0, in all segments.
At Weeks 4, 8, 16, 48, and 96
Absolute Value of International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) Through Week 96
Временное ограничение: Baseline up to Week 96

Absolute value of IBUS-SAS through Week 96 will be reported. IBUS-SAS score is defined as 4*BWT+15*IMF+7*CDS+4*BWS.
Baseline up to Week 96
Change from Baseline in International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) Through Week 96
Временное ограничение: Up to Week 96

Change from baseline in IBUS-SAS through Week 96 will be reported. IBUS-SAS score is defined as 4*BWT+15*IMF+7*CDS+4*BWS.
Up to Week 96
Percentage of Participants Achieving IBUS-SAS Response at Weeks 4, 8, 16, 48, and Week 96
Временное ограничение: Baseline, at Weeks 4, 8, 16, 48, and Week 96

Percentage of participants achieving IBUS-SAS response at Weeks 4, 8, 16, 48, and Week 96 will be reported. IBUS-SAS is defined as a reduction in IBUS-SAS score from baseline of >=10 points per baseline pathological segment and segmental score <=12 (if not pathological), at baseline.
Baseline, at Weeks 4, 8, 16, 48, and Week 96
Percentage of Participants Achieving BWT <=3 mm for Ileum and Colon Plus CDS 0, in all segments and Participants Not Receiving Corticosteroids at Weeks 4, 8, 16, 48, and 96
Временное ограничение: At Weeks 4, 8, 16, 48, and 96

Percentage of participants achieving BWT <=3 mm for Ileum and Colon plus CDS 0, in all segments at Weeks 4, 8, 16, 48, and 96 will be reported. Participants not receiving corticosteroids achieving BWT <=3 mm for Ileum and Colon plus CDS 0 at Weeks 4, 8, 16, 48, and 96 will be reported.
At Weeks 4, 8, 16, 48, and 96
Absolute Value of BWT through Week 96
Временное ограничение: Baseline up to Week 96

Absolute Value of BWT through Week 96 will be reported.
Baseline up to Week 96
Change From Baseline in BWT Through Week 96
Временное ограничение: Up to Week 96

Change from baseline in BWT through Week 96 will be reported.
Up to Week 96
Absolute Value of Simple IUS Score For CD (SUS-CD) Score Through Week 96
Временное ограничение: Baseline up to Week 96

Absolute value of SUS-CD score through Week 96 will be reported. SUS-CD is based on the sum of classifications for BWT and CDS for all segments.
Baseline up to Week 96
Change From Baseline in the SUS-CD Score Through Week 96
Временное ограничение: Up to Week 96

Change from Baseline in the SUS-CD score through Week 96 will be reported. SUS-CD is based on the sum of classifications for BWT and CDS for all segments.
Up to Week 96
Percentage of Participants Achieving Endoscopic Response at Weeks 48 and 96
Временное ограничение: Weeks 48 and 96

Percentage of participants with transmural response (total) at Weeks 48 and Week 96 will be reported. Endoscopic Response is defined as >=50% improvement from baseline in SES-CD total score or SES-CD <=2.
Weeks 48 and 96
Percentage of Participants Achieving Endoscopic Remission at Weeks 48 and 96
Временное ограничение: At Weeks 48 and 96

Percentage of participants achieving endoscopic remission at Weeks 48 and 96 will be reported. Endoscopic remission is defined as SES-CD total score <=4 with at least 2 points reduction from baseline and no sub-score >1 in any individual component.
At Weeks 48 and 96
Absolute Value of SES-CD Total Score Through Week 96
Временное ограничение: Baseline up to Week 96

Absolute value of SES-CD total score through Week 96 will be reported. The SES-CD score is used to evaluate endoscopic improvement. The SES-CD is based on the evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. An overall total SES-CD score is derived from the sum of all the component scores and can range from 0 to 56.
Baseline up to Week 96
Change From Baseline in the SES-CD Total Score Through Week 96
Временное ограничение: Up to Week 96

Change from baseline in the SES-CD total score through Week 96 will be reported. The SES-CD score is used to evaluate Endoscopic Improvement. The SES-CD is based on the evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any other lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. An overall total SES-CD score is derived from the sum of all the component scores and can range from 0 to 56.
Up to Week 96
Percentage of Participants (Not Receiving Corticosteroids) Achieving Endoscopic Remission at Weeks 48 and 96
Временное ограничение: Baseline, at Weeks 48 and 96

Percentage of participants (not receiving corticosteroids) achieving endoscopic remission at Weeks 48 and 96 will be reported. Endoscopic remission is defined as SES-CD total score <=4 with at least 2 points reduction from baseline and no sub-score >1 in any individual component.
Baseline, at Weeks 48 and 96
Percentage of Participants Achieving Endoscopic Healing of the Intestinal Mucosa at Weeks 48 and 96
Временное ограничение: At Weeks 48 and 96

Percentage of participants achieving endoscopic healing of the intestinal mucosa at Weeks 48 and 96 will be reported. Endoscopic healing is defined as the resolution (absence) of mucosal ulcers in response to a therapeutic intervention.
At Weeks 48 and 96
Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) <150 at Weeks 4, 8, 16, 48 and 96
Временное ограничение: At Weeks 4, 8, 16, 48 and 96

Percentage of participants achieving CDAI <150 at Weeks 4, 8, 16, 48 and 96 will be reported. CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain (AP)/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on daily basis.
At Weeks 4, 8, 16, 48 and 96
Percentage of Participants Achieving a Reduction in the CDAI Score of >=100 points or CDAI <150 From Baseline at Weeks 4, 8, 16, 48, and 96
Временное ограничение: At Weeks 4, 8, 16, 48, and 96

Percentage of participants achieving a reduction in the CDAI score of >=100 points or CDAI <150 from Baseline at Weeks 4, 8, 16, 48, and 96 will be reported. CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain (AP)/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on daily basis.
At Weeks 4, 8, 16, 48, and 96
Percentage of Participants (Not Receiving Corticosteroids) Achieving CDAI Score <150 at Weeks 4, 8, 16, 48 and 96
Временное ограничение: At Weeks 4, 8, 16, 48 and 96

Percentage of participants (not receiving corticosteroids) achieving CDAI Score <150 at Weeks 4, 8, 16, 48 and 96 will be reported. CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain (AP)/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on daily basis.
At Weeks 4, 8, 16, 48 and 96
Absolute Value of CDAI Score Through Week 96
Временное ограничение: Baseline up to Week 96

Absolute Value of CDAI score through Week 96 will be reported. CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain (AP)/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on daily basis.
Baseline up to Week 96
Change From Baseline in CDAI Score Through Week 96
Временное ограничение: Up to Week 96

Change from baseline in CDAI score through Week 96 will be reported. CDAI will be assessed by collecting information on 8 different Crohn's disease-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid or very soft stools, abdominal pain (AP)/cramping, use of antidiarrheal drug(s) and/or opiates, and general well-being. The last 4 variables are scored over 7 days by the participant on a diary card that participants are to complete on daily basis.
Up to Week 96
Percentage of Participants Achieving PRO-2 Remission at Weeks 4, 8, 16, 48, and Week 96
Временное ограничение: At Weeks 4, 8, 16, 48, and Week 96

Percentage of participants achieving PRO-2 remission at Weeks 4, 8, 16, 48, and Week 96 will be reported. PRO-2 remission is defined as AP mean daily score <=1 and a SF mean daily score <=3, and no worsening of AP or SF from baseline.
At Weeks 4, 8, 16, 48, and Week 96
Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Weeks 48 and 96
Временное ограничение: At Week 48 and Week 96

Percentage of participants achieving IBDQ remission at Weeks 48 and 96 will be reported. The IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD to evaluate PROs across 4 dimensions: bowel symptoms (loose stools, AP), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability).
At Week 48 and Week 96
Percentage of Participants Achieving IBDQ Response at Weeks 48 and 96
Временное ограничение: Baseline, at Weeks 48 and 96

Percentage of participants achieving IBDQ response at Weeks 48 and 96 will be reported. IBDQ response is defined as >=16-point improvement in IBDQ score from baseline. IBDQ score ranges from 32 to 224, with higher scores indicating better outcomes.
Baseline, at Weeks 48 and 96
Absolute Value of IBDQ Through Week 96
Временное ограничение: Baseline up to Week 96

Absolute value of IBDQ through Week 96 will be reported. The IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD to evaluate PROs across 4 dimensions: bowel symptoms (loose stools, AP), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.
Baseline up to Week 96
Change From Baseline in IBDQ Score Through Week 96
Временное ограничение: Up to Week 96

Change from baseline in IBDQ score through Week 96 will be reported. The IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD to evaluate PROs across 4 dimensions: bowel symptoms (loose stools, AP), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.
Up to Week 96
Change from Baseline in Urgency Numeric Rating Scale (UNRS) Through Week 96
Временное ограничение: Baseline up to Week 96

Change from baseline in UNRS through Week 96 will be reported. UNRS is designed to assess changes in the severity of bowel urgency (sudden or immediate need). Severity of bowel urgency is defined by the patient's perception of overall experience in which respondents consider the immediacy of bowel movement urgency severity over 24 h on an 11-point horizontal NRS ranging from 0 ('no urgency') to 10 ('worst possible urgency').
Baseline up to Week 96
Percentage of Participants Achieving C-reactive Protein (CRP) Normalization at Weeks 4, 8, 16, 48, and Week 96
Временное ограничение: Baseline, at Weeks 4, 8, 16, 48, and Week 96

CRP normalization is defined as CRP <=3 mg/L, among participants with baseline elevation in CRP (that is, >3 mg/L).
Baseline, at Weeks 4, 8, 16, 48, and Week 96
Percentage of Participants Achieving >=50% Improvement of CRP Response From Baseline at Weeks 4, 8, 16, 48, and 96
Временное ограничение: Baseline, at Weeks 4, 8, 16, 48, and 96

Percentage of participants achieving >=50% improvement of CRP response from baseline at Weeks 4, 8, 16, 48, and 96 will be reported.
Baseline, at Weeks 4, 8, 16, 48, and 96
Percentage of Participants Achieving fCal Normalization at Weeks 4, 8, 16, 48, and 96
Временное ограничение: Baseline, at Weeks 4, 8, 16, 48, and 96

Percentage of participants achieving fCal normalization at Weeks 4, 8, 16, 48, and 96 will be reported. fCal normalization is defined as fCal <=250 mcg/g among participants with elevated fCal at baseline.
Baseline, at Weeks 4, 8, 16, 48, and 96
Percentage of Participants Achieving >=50% Improvement of fCal Response From Baseline at Weeks 4, 8, 16, 48, and 96
Временное ограничение: Baseline, at Weeks 4, 8, 16, 48, and 96

Percentage of participants achieving >=50% improvement of fCal response from baseline at Weeks 4, 8, 16, 48, and 96 will be reported.
Baseline, at Weeks 4, 8, 16, 48, and 96
Change From Baseline in CRP and fCal Levels Over Time
Временное ограничение: Baseline, Weeks 4, 8, 16, 32, 48, and 96

Change from baseline in CRP and fCal levels over time will be reported.
Baseline, Weeks 4, 8, 16, 32, 48, and 96
Values of CRP and fCal Levels Over Time
Временное ограничение: Baseline, Weeks 4, 8, 16, 32, 48, and 96

Values of CRP and fCal levels over time will be reported.
Baseline, Weeks 4, 8, 16, 32, 48, and 96
Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TSAEs) Through Week 48
Временное ограничение: Up to Week 48

An AE is any untoward medical occurrence in a clinical study subject administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as the AEs occurring after first administration of study intervention (or worsened since then). An serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. TESAEs are defined as serious events between administration of study drug and after the last dose that were absent before treatment or that worsen relative to pretreatment state.
Up to Week 48

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Janssen-Cilag Ltd.

Следователи

  • Директор по исследованиям: Janssen Cilag Ltd. Clinical trial, Janssen-Cilag Ltd.

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

17 апреля 2024 г.

Первичное завершение (Оцененный)

8 июня 2027 г.

Завершение исследования (Оцененный)

6 марта 2028 г.

Даты регистрации исследования

Первый отправленный

7 мая 2024 г.

Впервые представлено, что соответствует критериям контроля качества

7 мая 2024 г.

Первый опубликованный (Действительный)

10 мая 2024 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

3 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

2 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Дополнительные соответствующие термины MeSH

Другие идентификационные номера исследования

  • CNTO1959CRD3008
  • CNTO1959CRD3008 (Другой идентификатор: Janssen Research & Development, LLC)
  • 2023-504040-34-00 (Идентификатор реестра: EUCT number)
  • 2023 (Грант/контракт NIH США)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться